Literature DB >> 33159691

Mitochondrial disorders of the OXPHOS system.

Erika Fernandez-Vizarra1, Massimo Zeviani2,3.   

Abstract

Mitochondrial disorders are among the most frequent inborn errors of metabolism, their primary cause being the dysfunction of the oxidative phosphorylation system (OXPHOS). OXPHOS is composed of the electron transport chain (ETC), formed by four multimeric enzymes and two mobile electron carriers, plus an ATP synthase [also called complex V (cV)]. The ETC performs the redox reactions involved in cellular respiration while generating the proton motive force used by cV to synthesize ATP. OXPHOS biogenesis involves multiple steps, starting from the expression of genes encoded in physically separated genomes, namely the mitochondrial and nuclear DNA, to the coordinated assembly of components and cofactors building each individual complex and eventually the supercomplexes. The genetic cause underlying around half of the diagnosed mitochondrial disease cases is currently known. Many of these cases result from pathogenic variants in genes encoding structural subunits or additional factors directly involved in the assembly of the ETC complexes. Here, we review the historical and most recent findings concerning the clinical phenotypes and the molecular pathological mechanisms underlying this particular group of disorders.
© 2020 Federation of European Biochemical Societies.

Entities:  

Keywords:  ATP production; biogenesis of the respiratory chain; mitochondrial disease; mitochondrial electrochemical gradient; mitochondrial potential; mitochondrial proton pumping; mitochondrial respiratory chain; oxidative phosphorylation; respiratory complex; respiratory supercomplex

Mesh:

Substances:

Year:  2020        PMID: 33159691     DOI: 10.1002/1873-3468.13995

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   3.864


  22 in total

Review 1.  The assembly, regulation and function of the mitochondrial respiratory chain.

Authors:  Irene Vercellino; Leonid A Sazanov
Journal:  Nat Rev Mol Cell Biol       Date:  2021-10-07       Impact factor: 94.444

2.  Respiratory complex I with charge symmetry in the membrane arm pumps protons.

Authors:  Franziska Hoeser; Hannes Tausend; Sinja Götz; Daniel Wohlwend; Oliver Einsle; Stefan Günther; Thorsten Friedrich
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-27       Impact factor: 12.779

3.  Expression of actin- and oxidative phosphorylation-related transcripts across the cortical visuospatial working memory network in unaffected comparison and schizophrenia subjects.

Authors:  Sohei Kimoto; Takanori Hashimoto; Kimberly J Berry; Makoto Tsubomoto; Yasunari Yamaguchi; John F Enwright; Kehui Chen; Rika Kawabata; Mitsuru Kikuchi; Toshifumi Kishimoto; David A Lewis
Journal:  Neuropsychopharmacology       Date:  2022-01-15       Impact factor: 8.294

4.  Characterization of drug-induced human mitochondrial ADP/ATP carrier inhibition.

Authors:  Stephany Jaiquel Baron; Martin S King; Edmund R S Kunji; Tom J J Schirris
Journal:  Theranostics       Date:  2021-03-05       Impact factor: 11.556

5.  Clinical Relevance and Tumor Growth Suppression of Mitochondrial ROS Regulators along NADH:Ubiquinone Oxidoreductase Subunit B3 in Thyroid Cancer.

Authors:  Jiao Zhu; Xiaobo Zheng; Dan Lu; Yun Zheng; Jun Liu
Journal:  Oxid Med Cell Longev       Date:  2022-01-17       Impact factor: 6.543

Review 6.  Mitochondrial Neurodegeneration.

Authors:  Massimo Zeviani; Carlo Viscomi
Journal:  Cells       Date:  2022-02-11       Impact factor: 6.600

Review 7.  Interplay between Mitochondrial Protein Import and Respiratory Complexes Assembly in Neuronal Health and Degeneration.

Authors:  Hope I Needs; Margherita Protasoni; Jeremy M Henley; Julien Prudent; Ian Collinson; Gonçalo C Pereira
Journal:  Life (Basel)       Date:  2021-05-11

Review 8.  Allicin, an Antioxidant and Neuroprotective Agent, Ameliorates Cognitive Impairment.

Authors:  Muhammad Shahid Nadeem; Imran Kazmi; Inam Ullah; Khushi Muhammad; Firoz Anwar
Journal:  Antioxidants (Basel)       Date:  2021-12-30

9.  Olaparib: A Clinically Applied PARP Inhibitor Protects from Experimental Crohn's Disease and Maintains Barrier Integrity by Improving Bioenergetics through Rescuing Glycolysis in Colonic Epithelial Cells.

Authors:  Dominika Kovács; Viola Bagóné Vántus; Eszter Vámos; Nikoletta Kálmán; Rudolf Schicho; Ferenc Gallyas; Balázs Radnai
Journal:  Oxid Med Cell Longev       Date:  2021-09-14       Impact factor: 6.543

Review 10.  Molecular Insights into Mitochondrial Protein Translocation and Human Disease.

Authors:  Eduardo Ruiz-Pesini; Julio Montoya; David Pacheu-Grau
Journal:  Genes (Basel)       Date:  2021-07-01       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.